Business Context and Reporting Period
This Form 8-K Current Report was filed by vTv Therapeutics Inc. on December 11, 2018. The filing discloses a material definitive agreement with MacAndrews & Forbes Group LLC and the initiation of a significant corporate restructuring.
Key Financial Metrics and Agreements
- Financing Commitment: Entered into a Letter Agreement with MacAndrews & Forbes Group LLC for a potential investment of up to $10.0 million in Class A common stock.
- Share Price: The commitment price is set at $1.84 per share, equal to the closing price on December 10, 2018.
- Warrants Issued: The Investor received warrants to purchase 340,534 shares at an exercise price of $2.12 per share (115% of the option price), exercisable until December 11, 2025.
- Restructuring Costs: The Company expects a one-time restructuring charge of approximately $0.8 million for employee severance and related costs.
- Cost Savings: The restructuring is projected to yield annualized cost savings of approximately $3.7 million.
- Ownership: As of the filing date, subsidiaries and affiliates of the Investor held approximately 83.3% of the Company's combined voting power.
Material Changes and Restructuring
The Company initiated a strategic shift to utilize external resources for drug development rather than internal resources. This decision resulted in a workforce reduction affecting approximately 65% of employees as of December 11, 2018. The Company expects to complete headcount reductions and associated severance payments in the second quarter of 2019. While annualized savings are estimated at $3.7 million, the filing notes that some savings may be offset by higher costs for outsourced services, which cannot be quantified at this time.
Outlook, Risks, and Contingencies
- Strategic Focus: The restructuring aims to reduce costs while continuing clinical trials, specifically the Simplici-T1 study in type 1 diabetes, and supporting existing partnerships.
- Investment Flexibility: The $10.0 million investment commitment is exercisable on demand by the Company or up to three times by the Investor during a one-year period, subject to the execution of definitive documentation.
- Related Party Transactions: Two Company directors are employees of the Investor, and the transaction was approved under the Related Person Transactions Policy.
- Unregistered Securities: The issuance of Common Stock and Warrants relies on an exemption under Regulation D of the Securities Act of 1933.
Key Facts for Investor Verification
- Verify the execution of definitive documentation required to trigger the $10.0 million funding commitment.
- Monitor the actual completion of the 65% workforce reduction and the timing of the $0.8 million severance charge in Q2 2019.
- Assess the impact of increased outsourcing costs on the projected $3.7 million in annualized savings.
- Review the progress of the Simplici-T1 clinical trial given the shift to external development resources.
- Confirm the Investor's continued majority voting control (83.3%) and its implications for corporate governance.